A ‘best practice’: ACRO, pharma respond to FDA draft guidance as RBM adoption increases

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Olivier Le Moal)
(Image: Getty/Olivier Le Moal)

Related tags Risk-based monitoring RBM Acro Fda

Risk-based monitoring should be described as a “best practice,” says ACRO, which recently released a survey that found the majority of new trial starts in 2018 employed some form of RBM.

The US Food and Drug Administration (FDA) recently expanded on its recommendations​ for taking risk-based approaches to clinical trial monitoring in a new draft guidance​​.

Structured as a question and answer (Q&A), the document builds on the agency’s risk-based monitoring (RBM) guidance​ and was open for comment until May 14, 2019.

Responding, the Association of Clinical Research Organizations (ACRO) submitted comments​ on the recent draft guidance, calling on the FDA to describe RBM as a “best practice,”​ among other proposed changes. “ACRO believes that a stronger statement about the place of risk-based monitoring in the oversight toolbox would be useful,”​ the comment reads.

ACRO also noted that the guidance does not resolve questions about the definition of central monitoring.

Others commented as well, including Bristol-Myers Squibb​ (BMS) and Pfizer​, which raised areas where it said the industry would benefit from additional clarification. This included inspections, identifying risk to good clinical practice, and measuring success of a risk-based approach.

Pfizer suggested working with the Clinical Trials Transformation Initiative (CTTI) to collect data “to determine whether the factors noted as potentially important are important to quality outcomes.”

RBM adoption rates

ACRO Executive Director, Doug Peddicord told us, “Sponsors and CROs are committed to risk-based approaches to trial design and monitoring planning, and at this point always include risk-based principles in their planning.”

In line with this, ACRO recently surveyed its members regarding their RBM processes and implementation and found that adoption is accelerating.

(Image credit: ACRO)
(Image credit: ACRO)

Per the report, less than 20% of new trial starts employed some form of RBM oversight in 2016 – the year ICH E6 (R2) was issued, encouraging the use of RBM, which Peddicord said helped drive penetration.

By 2018, the majority of new trial starts were using RBM (61%), according to the survey. Still, challenges remain, including the perceived notion that traditional oversight methods are lower risk and less subject to regulator scrutiny.

“All of us – sponsors, CROs, technology companies, research sites, IRBs – hope that increasing adoption of technology-enabled tools will, over time, reduce some of the burdens of participation for patients and investigators alike,”​ said Peddicord.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us

Products

View more

Webinars